StreetAlpha.app
Home › Stocks › AVXL

Anavex Life Sciences Corp. (AVXL)

$0.74
▼ −9.49%
LAST CLOSE · NOV 17

Anavex Life Sciences is a New York biopharmaceutical company developing drug candidates for Alzheimer's and other brain diseases. It last closed at $0.74 on Nov 17, down 9.49% on the day. AVXL reports earnings on Tue, Nov 24, 2026.

AI Auto Pilots
Is AVXL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$13.0M
EPS (diluted)
−$0.14
Valuation
Market cap
$68.6M
92.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$118.3M
At Jun 30
Shareholder equity
$112.4M
Shares outstanding
92.7M
At Aug 28
Fiscal year endsSeptember
ExchangeNasdaq
Financials history
FY2021: −$37.9M−$37.9MFY2021FY2022: −$48.0M−$48.0MFY2022FY2023: −$47.5M−$47.5MFY2023FY2024: −$43.0M−$43.0MFY2024FY2025: −$46.4M−$46.4MFY2025

From AVXL's SEC filings, latest 10-Q for the period ending Jun 30, 2026 (filed Aug 28). Last 12 months adds up the four latest quarters.

Next report
Nov 24
2026 · Time not announced
Consensus EPS forecast
-$0.11
 
Year-ago EPS
-$0.11
Same quarter last year
Options-implied move
—
Posted about a week before
Analyst consensus
—
No ratings in 90 days
Loading…

Technical Analysis

AVXL · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 57% below its 20 day and 126% below its 50 day average. It is 286% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 20), oversold. The nearest support is the 52 week low at $0.71, and the nearest resistance the Pivot at $0.76.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 14.8%/day
Key levels
$5.3652 week high+624.3%
$2.86200 day average+286.5%
$2.27100 day average+206.8%
$1.6750 day average+125.7%
$1.32Swing high (Oct 29)+78.4%
$1.1620 day average+56.8%
$0.82Pivot R1+10.8%
$0.76Pivot+2.7%
$0.74Last close
$0.7152 week low−4.1%
$0.69Pivot S1−6.8%
Indicators
RSI (14)20.33Oversold below 30Oversold
MACD-0.22Below its signal lineBearish
Stochastic4.3Near the bottom of its rangeOversold
ADX (14)55.5Strong downtrend
Williams %R-94.7Oversold below −80, overbought above −20Oversold
CCI (20)-215.7Oversold below −100, overbought above 100Oversold
Rate of change−38.3%Change over 10 sessionsBearish
ATR (14)$0.11Typical daily range, 14.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AVXL

What happened before

See how AVXL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Earnings in 6 daysSignals right before a report are less reliable. The report can override them.
November seasonalityHow AVXL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AVXL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in AVXL in the last 90 days.

Loading…

See today’s whale options flow across the market →

AVXL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼56 buying vs 96 selling
  • ▲Held by funds +2.6 pts
  • ▼Funds holding -16
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding165181−8.8%
In funds' top 1000–
Held by funds42.6%40.0%+2.6 pts
New / increased14 / 4223 / 65−36.4%
Reduced / sold out70 / 2654 / 32+11.6%
Put/call ratio0.020.00+1983.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AVXL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AVXL is in one of them and how their past AVXL trades turned out.

AVXL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AVXL in an article yet. Here's the latest on the wider market.

AVXL Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Jan 20
Who traded AVXL · since 2022
Latest 2 filings
$1K – $15KTraded Dec 12, 2022Filed Jan 20, 2023
$1K – $15KTraded Oct 12, 2022Filed Nov 16, 2022
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYSell$1K – $15KDec 12, 2022Jan 20, 202339 d
Christopher JacobsR · NYBuy$1K – $15KOct 12, 2022Nov 16, 202235 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Anavex Life Sciences

Anavex Life Sciences is a clinical stage biopharmaceutical company based in New York. It develops drug candidates for diseases of the central nervous system, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome and other rare brain disorders. Its main candidate, blarcamesine, is being studied as an oral treatment that acts on the sigma receptor. The company's intended customers are patients with these conditions and the healthcare providers who treat them.

Headquarters
New York, NY